When was Aizant founded?

Aizant was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Where is Aizant located?

Aizant is headquartered in Hyderabad, India. It is registered at Sy No.172 /173, Apparel Park Road, Dulapally Vil. Dundigal Gandimaisamma Mdl, Medchal - Ma, lkajgiri, Rangareddi, Hyderabad, Telangana, India, 500100.

Who is the current CEO of Aizant?

Varma Srinivasa Rajasekara Rudraraju of Aizant. They have also founded 1 company.

Which legal entities is Aizant associated with?

Aizant is associated with AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED.

How many employees does Aizant have?

As of Aug 31, 2025, Aizant has 759 employees, reflecting a 1% year-over-year growth in headcount.

Is Aizant a funded company?

Aizant is a funded company, having raised a total of $7.59M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 01, 2007.

How much is Aizant worth?

The latest valuation of Aizant is ₹***** as of Mar 26, 2017.

When was the latest funding round of Aizant?

Aizant's latest funding was a $***** Series A round on Mar 26, 2017, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In India, the Biopharma Outsourcing sector has seen $349M in funding in 2026 to date.

What is the annual revenue of Aizant?

Annual revenue of Aizant is between ₹100 Cr and ₹500 Cr as on Mar 31, 2025

Where does Aizant rank among its competitors?

Aizant ranks 6th amongst 296 active competitors, of which 23 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was LYOCONTRACT, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Aizant?

Aizant's top competitors include Suanfarma, Nephron Pharmaceuticals and Quotient Sciences. Among them, LYOCONTRACT secured the most recent funding round in May, 2026.

Aizant - 2026 Company Profile, Team, Funding, Competitors & Financials

Aizant is a series A company based in Hyderabad (India), founded in 2005 by Varma Srinivasa Rajasekara Rudraraju. It operates as a Company offering contract development services for small molecules. Aizant has raised $7.59M in funding from investors like Zephyr Peacock, Zephyr Management and Pearl Lane Coinvest, with a current valuation of ₹*****. The company has 296 active competitors, including 23 funded and 19 that have exited. Its top competitors include companies like Suanfarma, Nephron Pharmaceuticals and Quotient Sciences.

Company Details

Website: www.aizant.com/
Social
Email ID: *****@aizant.com
Phone Number: +91 **********
Registered Address: Sy No.172 /173, Apparel Park Road, Dulapally Vil. Dundigal Gandimaisamma Mdl, Medchal - Ma, lkajgiri, Rangareddi, Hyderabad, Telangana, India, 500100

Key Metrics

Founded Year

2005

Location

Hyderabad, India

Stage

Series A

Total Funding

$7.59M in 3 rounds

Latest Funding Round

Series A, Mar 26, 2017, $*****

Post Money Valuation

₹***** as on Mar 26, 2017

Investors

Zephyr Peacock & 40 more

Ranked

6^th among 296 active competitors

Annual Revenue

₹100 - ₹500 Cr as on Mar 31, 2025

Employee Count

759 as on Aug 31, 2025

Similar Companies

Suanfarma & 300 more

View Aizant's full profile

Aizant is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED CIN: U24239TG2005PTC048133 , India, Active	Nov 22, 2005	₹100 - ₹500 Cr (As on Mar 31, 2025)	790 (As on May 01, 2026)

Aizant has raised a total funding of $7.59M over 3 rounds. Its first funding round was on Dec 01, 2007. Its latest funding round was a Series A round on Mar 26, 2017 for $*****. 1 investor participated in its latest round. Aizant has 13 institutional investors and 28 angel investors.

Here is the list of recent funding rounds of Aizant:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 26, 2017	3341152	Series A	6441234	7250782	4996902	8541946
Jan 14, 2011	5255194	Series A	9132320	6009809	5279922	Tarun Shah
Dec 01, 2007	1056029	Seed	3498983	1742175	Anirudh Mundra	Mafatlal Industries & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of Aizant's funding rounds and investors

The founders of Aizant is Varma Srinivasa Rajasekara Rudraraju. Varma Srinivasa Rajasekara Rudraraju is the CEO of Aizant.

Here are the details of Aizant's key team members:

Varma Srinivasa Rajasekara Rudraraju: Founder, CEO & Chairman of Aizant. They serve on the board of 1 company.
Contact Info: 1 email address and 1 phone number

Aizant's Board of Directors

Aizant's board has 4 active members. Varma Srinivasa Rajasekara Rudraraju is part of team and Sanjeev Kumar Sethi, Soumya Rudraraju and Rudraraju Sneha are independent board members.

Here is the list of Aizant's board of directors:

Name	Type	Representing	Status	Duration
xito{gu	Team	-	Current	3y 8m
Sanjeev Kumar Sethi	Independent board member	-	Current	2y 1m
wynprrc	Independent board member	-	Current	5y 1m
lhycgyw	Independent board member	-	Current	5y 9m

View details of Aizant's Founder profiles and Board Members

Aizant's employee count trend

Aizant has 759 employees as of Aug 25. The total employee count is 1.0% more than what it was in Aug 24. Here is Aizant's employee count trend over the years:

Uncover Aizant's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aizant include Suanfarma, Nephron Pharmaceuticals and Quotient Sciences. Here is the list of Top 10 competitors of Aizant, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Suanfarma 1993, Madrid (Spain), Acquired	Developer of generics, nutraceuticals, and APIs	-	ProA Capital, Hermes GPE	60/100
2nd	Nephron Pharmaceuticals 1937, Florida (Puerto Rico), Late Stage	Manufacturer of sterile pharmaceutical products and provider of contract manufacturing and 503B outsourcing services	$625M	Blackrockbkcc, PNC & 3 others	59/100
3rd	Quotient Sciences 1990, Nottingham (United Kingdom), Acquired	Developer and manufacturer of APIs as well as finished dosage forms	-	TA Associates, GHO Capital Partners & 1 others	55/100
4th	OneSource 1990, Bengaluru (India), Public	Pharmaceutical contract development and manufacturing organization offering pharmaceutical products	$155M	Erasmic Venture Fund, Tenshi Life Sciences ... & 15 others	54/100
5th	Wheeler Bio 2020, Oklahoma City (United States), Series A	Provider of drug research and analytical development services for multiple therapeutic areas	$103M	Echo, Charles River Laboratories & 14 others	53/100
6th	Aizant 2005, Hyderabad (India), Series A	Company offering contract development services for small molecules	$7.59M	InvAscent, Zephyr Management & 39 others	50/100
7th	LSL Pharma Group 2023, Boucherville (Canada), Public	Integrated pharmaceutical company provides pharma products	-	-	47/100
8th	Aiolos Bio 2023, Boston (United States), Acquired	Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions	$245M	Bain Capital Life Sciences, Atlas Venture ... & 3 others	47/100
9th	LYOCONTRACT 2007, Ilsenburg (Germany), Acquired	Provider of a pharmaceutical manufacturing site with capabilities for producing liquid and freeze-dried parenteral drugs in vials	-	Partners Group, Great Point Partners	45/100
10th	Antibiotice 1955, Iasi (Romania), Funding Raised	Manufacturer of human and veterinary medicines, active substances, and medical devices	-	HKK Partners	45/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Aizant's competitors? Click here to see the top ones

AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED, the legal entity associated with Aizant, generated between ₹100 Cr and ₹500 Cr in revenue for the financial year ending on Mar 31, 2025. The revenue of AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED has a compounded annual growth rate (CAGR) of 7% in the last 1 year.

Financial Statement Summary

Metrics	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Income Statement
Revenue	4169	8085	1867	9267
Total Sales	9499	7503	6120	2297
Total Expenses	3888	1129	5296	3530
Operating Expenses	8191	9769	6983	2383
Employee Expenses	3132	8355	9143	4075
Marketing Expenses	1110	5390	1848	4523
Operating Income (EBIT)	5843	3763	9774	7822
Interest Expenses	2400	2763	4579	9116
Expenses from other activities	9244	6717	1929	3315
EBITDA	6528	9286	7986	4828
Taxes	2755	6022	9213	8227
Net Profit	8723	9474	6450	1781
Balance Sheet
Assets	5943	4240	4937	1536
Cash Equivalent	4123	9702	6639	1547
Accounts Receivables	3057	2524	4911	9354
Inventory	6452	8888	3482	5966
Liabilities	3457	2043	3477	3174
Total Debt	5523	5447	5481	2442
Accounts Payable	8448	7939	6005	6336
Equities	9896	8761	3520	4661
Cashflow Statement
Cash from Operating activities	9369	4246	8288	4933
Cash from Investing activities	3112	1137	2089	5938
Net cash from Financing activities	8698	5387	7430	9554

Detailed Financials (Income Statement, Balance Sheet, Cashflow Statement)

Founders (largest shareholder) own 36.63%, Funds own 15.51%, Enterprises own 18.96% and Angels own 4.70%. The net worth of Aizant's founders is INR 125Cr as of Mar 26, 2017. The cap table displayed below is for AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED which is the legal entity associated with Aizant.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	36.63%	125Cr	3421595	2499766	8842494	9626800
Varma Srinivasa Rajasekara Rudraraju	4501071	2828688	5935639	8829017	6858639	2577648
Fund	15.51%	52.8Cr	9545747	9479597	7101244	4319034
Zephyr Management	3563369	3424904	8621077	1852565	1269960	5915340
Enterprise	18.96%	64.6Cr	7731527	7181686	9718560	7507318
Angel	4.70%	17.2Cr	7342	2802	7264	7231
Anirudh Mundra	813	633	168	378	771	353
Other People	24.19%	82.4Cr	7839838	3039999	4064046	5835087
Total	100.00%	342Cr	5134546	7126184	4316384	3013098